{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:23Z","timestamp":1792782803787,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg","id":[{"id":"https:\/\/ror.org\/03vzbgh69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although quetiapine is increasingly used off-label in children and adolescents with various psychiatric disorders, there is little evidence on the relationship between quetiapine dose and serum concentration, and therapeutic reference ranges (TRR) have not yet been established for this age group. The aim of this study was to evaluate whether the TRR described for adults is applicable to minors. In addition, the study aimed to investigate the relationship between the daily dose, serum concentration and clinical outcome. The clinical course of 77 patients (females\u2009=\u200978%) aged between 12 and 17 years treated with quetiapine in the multicentre pharmacovigilance study TDM-VIGIL was systematically followed, and serum concentrations were measured. A positive mean correlation was observed between the weight-adjusted daily dose and serum concentration (\n                    <jats:italic>r<\/jats:italic>\n                    <jats:sub>s<\/jats:sub>\n                    = 0.580,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Most patients (84.7%) experienced no ADRs or ADRs not significantly interfering with the patients\u2019 functioning. A positive linear relationship between the therapeutic response and serum concentration was found (\n                    <jats:italic>r<\/jats:italic>\n                    <jats:sub>s<\/jats:sub>\n                    = 0.238,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006). Only 38.5% of all quetiapine serum concentrations were within the recommended TRR described for adults. Using two different calculation methods, mean\u2009\u00b1\u2009SD and IQR, our data hinted at considerably lower TRR for minors of about 14\u2013291 ng\/ml and 53\u2013234 ng\/ml respectively, compared to the suggested TRR for adults. This study has the potential to contribute to the definition of a TRR for quetiapine in minors. However, further controlled studies with larger sample sizes are needed to verify the preliminary results.\n                  <\/jats:p>","DOI":"10.1007\/s00702-026-03253-6","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:46:52Z","timestamp":1786960012000},"page":"2715-2731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic drug monitoring in children and adolescents treated with quetiapine for different psychiatric disorders: results of the TDM-VIGIL pharmacovigilance study"],"prefix":"10.1007","volume":"133","author":[{"given":"Alina","family":"Kaiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Maria","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Willi","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Romanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Karwautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Plener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Malzahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Heuschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Rock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Banaschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Imgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kaess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yin","family":"Reuter-Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Schulte-K\u00f6rne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Walitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fleischhaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"3253_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/0269881105053306","volume":"19","author":"W Aichhorn","year":"2005","unstructured":"Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig-Schoeler R, Stuppaeck C, Geretsegger C (2005) Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 19:395\u2013401. https:\/\/doi.org\/10.1177\/0269881105053306","journal-title":"J Psychopharmacol"},{"key":"3253_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/01.yic.0000188213.46667.f1","volume":"21","author":"W Aichhorn","year":"2006","unstructured":"Aichhorn W, Marksteiner J, Walch T, Zernig G, Saria A, Kemmler G (2006) Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 21:81\u201385. https:\/\/doi.org\/10.1097\/01.yic.0000188213.46667.f1","journal-title":"Int Clin Psychopharmacol"},{"key":"3253_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1055\/s-0043-109695","volume":"50","author":"L Albantakis","year":"2017","unstructured":"Albantakis L, Egberts K, Burger R, Kulpok C, Mehler-Wex C, Taurines R, Unterecker S, Wewetzer C, Romanos M, Gerlach M (2017) Relationship Between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders. Pharmacopsychiatry 50:248\u2013255. https:\/\/doi.org\/10.1055\/s-0043-109695","journal-title":"Pharmacopsychiatry"},{"key":"3253_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00787-016-0866-x","volume":"26","author":"I Baeza","year":"2017","unstructured":"Baeza I, Vigo L, de la Serna E, Calvo-Escalona R, Merch\u00e1n-Naranjo J, Rodr\u00edguez-Latorre P, Arango C, Castro-Fornieles J (2017) The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. Eur Child Adolesc Psychiatry 26:35\u201346. https:\/\/doi.org\/10.1007\/s00787-016-0866-x","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"3253_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1185\/030079904125004510","volume":"20","author":"PF Buckley","year":"2004","unstructured":"Buckley PF (2004) Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 20:1357\u20131363. https:\/\/doi.org\/10.1185\/030079904125004510","journal-title":"Curr Med Res Opin"},{"key":"3253_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1185\/03007995.2013.794774","volume":"29","author":"K Bui","year":"2013","unstructured":"Bui K, Earley W, Nyberg S (2013) Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Curr Med Res Opin 29:813\u2013825. https:\/\/doi.org\/10.1185\/03007995.2013.794774","journal-title":"Curr Med Res Opin"},{"key":"3253_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.4088\/jcp.v68n1011","volume":"68","author":"I Castberg","year":"2007","unstructured":"Castberg I, Skogvoll E, Spigset O (2007) Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 68:1540\u20131545. https:\/\/doi.org\/10.4088\/jcp.v68n1011","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 4","key":"3253_CR8","first-page":"26","volume":"69","author":"CU Correll","year":"2008","unstructured":"Correll CU (2008) Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69(Suppl 4):26\u201336","journal-title":"J Clin Psychiatry"},{"key":"3253_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","volume":"45","author":"CU Correll","year":"2006","unstructured":"Correll CU, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771\u2013791. https:\/\/doi.org\/10.1097\/01.chi.0000220851.94392.30","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3253_CR10","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765\u20131773. https:\/\/doi.org\/10.1001\/jama.2009.1549","journal-title":"JAMA"},{"key":"3253_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12991-016-0096-0","volume":"15","author":"C Datto","year":"2016","unstructured":"Datto C, Pottorf WJ, Feeley L, LaPorte S, Liss C (2016) Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. Ann Gen Psychiatry 15:9. https:\/\/doi.org\/10.1186\/s12991-016-0096-0","journal-title":"Ann Gen Psychiatry"},{"key":"3253_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/01.chi.0000194567.63289.97","volume":"45","author":"MP Delbello","year":"2006","unstructured":"Delbello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, Nelson E, Strakowski SM (2006) A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 45:305\u2013313. https:\/\/doi.org\/10.1097\/01.chi.0000194567.63289.97","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3253_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","volume":"40","author":"CL DeVane","year":"2001","unstructured":"DeVane CL, Nemeroff CB (2001) Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 40:509\u2013522. https:\/\/doi.org\/10.2165\/00003088-200140070-00003","journal-title":"Clin Pharmacokinet"},{"key":"3253_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1055\/s-0031-1286291","volume":"44","author":"K Egberts","year":"2011","unstructured":"Egberts K, Mehler-Wex C, Gerlach M (2011) Therapeutic drug monitoring in child and adolescent psychiatry*. Pharmacopsychiatry 44:249\u2013253. https:\/\/doi.org\/10.1055\/s-0031-1286291","journal-title":"Pharmacopsychiatry"},{"key":"3253_CR15","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s00702-020-02253-4","volume":"127","author":"K Egberts","year":"2020","unstructured":"Egberts K, Reuter-Dang S-Y, Fekete S, Kulpok C, Mehler-Wex C, Wewetzer C, Karwautz A, Mitterer M, Holtkamp K, Boege I, Burger R, Romanos M, Gerlach M, Taurines R (2020) Therapeutic drug monitoring of children and adolescents treated with aripiprazole: observational results from routine patient care. J Neural Transm (Vienna) 127:1663\u20131674. https:\/\/doi.org\/10.1007\/s00702-020-02253-4","journal-title":"J Neural Transm (Vienna)"},{"key":"3253_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1055\/a-1716-1856","volume":"55","author":"KM Egberts","year":"2022","unstructured":"Egberts KM, Gerlach M, Correll CU, Plener PL, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleischhaker C, H\u00e4ge A, Hellenschmidt T, Imgart H, Kaess M, Karwautz A, K\u00f6lch M, Reitzle K, Renner T, Reuter-Dang S-Y, Rexroth C, Schulte-K\u00f6rne G, Theisen FM, Walitza S, Wewetzer C, Fekete S, Taurines R, Romanos M (2022) Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice. Pharmacopsychiatry 55:255\u2013265. https:\/\/doi.org\/10.1055\/a-1716-1856","journal-title":"Pharmacopsychiatry"},{"key":"3253_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/FTD.0000000000000685","volume":"42","author":"S Fekete","year":"2020","unstructured":"Fekete S, Hiemke C, Gerlach M (2020) Dose-Related Concentrations of Neuroactive\/Psychoactive Drugs Expected in Blood of Children and Adolescents. Ther Drug Monit 42:315\u2013324. https:\/\/doi.org\/10.1097\/FTD.0000000000000685","journal-title":"Ther Drug Monit"},{"key":"3253_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1055\/a-1963-7631","volume":"56","author":"S Fekete","year":"2023","unstructured":"Fekete S, G\u00fcntzel T, Egberts K, Geissler J, Neubert A, Gerlach M, Romanos M, Taurines R (2023) Serious Adverse Drug Reactions to Antipsychotics in Minors with Multiple Disabilities: Preventability and Potential Cost Savings by Therapeutic Drug Monitoring. Pharmacopsychiatry 56:32\u201339. https:\/\/doi.org\/10.1055\/a-1963-7631","journal-title":"Pharmacopsychiatry"},{"key":"3253_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.pnpbp.2008.09.026","volume":"33","author":"C Figueroa","year":"2009","unstructured":"Figueroa C, Brecher M, Hamer-Maansson JE, Winter H (2009) Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 33:199\u2013204. https:\/\/doi.org\/10.1016\/j.pnpbp.2008.09.026","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3253_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1089\/cap.2011.0092","volume":"22","author":"RL Findling","year":"2012","unstructured":"Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S (2012) Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 22:327\u2013342. https:\/\/doi.org\/10.1089\/cap.2011.0092","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"3253_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1089\/cap.2012.0092","volume":"23","author":"RL Findling","year":"2013","unstructured":"Findling RL, Pathak S, Earley WR, Liu S, DelBello M (2013) Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. J Child Adolesc Psychopharmacol 23:490\u2013501. https:\/\/doi.org\/10.1089\/cap.2012.0092","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"3253_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1055\/s-2007-972573","volume":"40","author":"M Gerlach","year":"2007","unstructured":"Gerlach M, H\u00fcnnerkopf R, Rothenh\u00f6fer S, Libal G, Burger R, Clement H-W, Fegert J, Wewetzer C, Mehler-Wex C (2007) Therapeutic Drug Monitoring of Quetiapine in Adolescents with Psychotic Disorders. Pharmacopsychiatry 40:72\u201376. https:\/\/doi.org\/10.1055\/s-2007-972573","journal-title":"Pharmacopsychiatry"},{"key":"3253_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-1501-5","volume-title":"Psychiatric Drugs in Children and Adolescents: Basic Pharmacology and Practical Applications","year":"2014","unstructured":"Gerlach M, Warnke A, Greenhill L (eds) (2014) Psychiatric Drugs in Children and Adolescents: Basic Pharmacology and Practical Applications. Springer Vienna, Vienna. https:\/\/doi.org\/10.1007\/978-3-7091-1501-5"},{"key":"3253_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","volume":"61","author":"SW Grimm","year":"2006","unstructured":"Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB (2006) Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 61:58\u201369. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02507.x","journal-title":"Br J Clin Pharmacol"},{"key":"3253_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.787043","volume":"12","author":"XM Hart","year":"2021","unstructured":"Hart XM, Eichentopf L, Lense X, Riemer T, Wesner K, Hiemke C, Gr\u00fcnder G (2021) Therapeutic reference ranges for psychotropic drugs: a protocol for systematic reviews. Front Psychiatry 12:787043. https:\/\/doi.org\/10.3389\/fpsyt.2021.787043","journal-title":"Front Psychiatry"},{"key":"3253_CR26","doi-asserted-by":"publisher","DOI":"10.1055\/a-2860-7861","author":"XM Hart","year":"2026","unstructured":"Hart XM, Gr\u00fcnder G, Hiemke C, Adamovic I, Amann F, Baumann P, Bergemann N, Brandt C, Clement H-W, Conca A, Deckert J, Dietmaier O, Eckermann G, Egberts K, Endres K, Erlacher N, Fekete S, Ferrea S, Florio V, Gerlach M, Haen E, Hahn M, Havemann-Reinecke U, Hefner G, Jost WH, Kuzin M, Laux G, Leucht S, Maniscalco I, Menke A, Messer T, Moessner R, M\u00fcller DJ, M\u00fcller T, Paulzen M, Petri H, Pfeifer P, Pfuhlmann B, Riederer P, Roll SC, Scherf-Clavel M, Schwarz M, Steimer W, Stingl JC, Toto S, Ulrich S, Zernig G, Zurek G, Unterecker S, Schoretsanitis G (2026) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2026 \u2013 pharmacokinetic, pharmacogenetic and clinical aspects. Pharmacopsychiatry. https:\/\/doi.org\/10.1055\/a-2860-7861","journal-title":"Pharmacopsychiatry"},{"key":"3253_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/FTD.0000000000001161","volume":"46","author":"RA Hermans","year":"2024","unstructured":"Hermans RA, Storm AEM, Kloosterboer SM, Hillegers MHJ, Koch BCP, Dierckx B, De Winter BCM (2024) Therapeutic drug monitoring to optimize risperidone treatment in children with autism spectrum disorder. Ther Drug Monit 46:259\u2013264. https:\/\/doi.org\/10.1097\/FTD.0000000000001161","journal-title":"Ther Drug Monit"},{"key":"3253_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gr\u00fcnder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, M\u00f6ssner R, M\u00fcller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492","journal-title":"Pharmacopsychiatry"},{"key":"3253_CR29","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","volume":"33","author":"NH Jensen","year":"2008","unstructured":"Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008) N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine\u2019s Antidepressant Activity. Neuropsychopharmacol 33:2303\u20132312. https:\/\/doi.org\/10.1038\/sj.npp.1301646","journal-title":"Neuropsychopharmacol"},{"key":"3253_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.jad.2011.09.042","volume":"136","author":"G Joshi","year":"2012","unstructured":"Joshi G, Petty C, Wozniak J, Faraone SV, Doyle R, Georgiopoulos A, Hammerness P, Walls S, Glaeser B, Brethel K, Yorks D, Biederman J (2012) A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. J Affect Disord 136:1143\u20131153. https:\/\/doi.org\/10.1016\/j.jad.2011.09.042","journal-title":"J Affect Disord"},{"key":"3253_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/14740338.2020.1770224","volume":"19","author":"SM Kloosterboer","year":"2020","unstructured":"Kloosterboer SM, Vierhout D, Stojanova J, Egberts KM, Gerlach M, Dieleman GC, Hillegers MHJ, Passe KM, Gelder TV, Dierckx B, Koch BCP (2020) Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review. Exp Opin Drug Saf 19:873\u2013890. https:\/\/doi.org\/10.1080\/14740338.2020.1770224","journal-title":"Exp Opin Drug Saf"},{"key":"3253_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (London, England) 373:31\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(08)61764-X","journal-title":"Lancet (London, England)"},{"key":"3253_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5863\/1551-6776-19.4.262","volume":"19","author":"H Lu","year":"2014","unstructured":"Lu H, Rosenbaum S (2014) Developmental Pharmacokinetics in Pediatric Populations. J Pediatr Pharmacol Ther 19:262\u2013276. https:\/\/doi.org\/10.5863\/1551-6776-19.4.262","journal-title":"J Pediatr Pharmacol Ther"},{"key":"3253_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4088\/jcp.v69n0111","volume":"69","author":"DC Mamo","year":"2008","unstructured":"Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S (2008) Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 69:81\u201386. https:\/\/doi.org\/10.4088\/jcp.v69n0111","journal-title":"J Clin Psychiatry"},{"key":"3253_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4088\/jcp.v61n0403","volume":"61","author":"BJ McConville","year":"2000","unstructured":"McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE (2000) Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252\u2013260. https:\/\/doi.org\/10.4088\/jcp.v61n0403","journal-title":"J Clin Psychiatry"},{"key":"3253_CR36","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s00213-018-4977-6","volume":"235","author":"M Murasaki","year":"2018","unstructured":"Murasaki M, Koyama T, Kanba S, Takeuchi M, Shimizu Y, Arita E, Kuroishi K, Takeuchi M, Kamei S (2018) Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression. Psychopharmacology 235:2859\u20132869. https:\/\/doi.org\/10.1007\/s00213-018-4977-6","journal-title":"Psychopharmacology"},{"key":"3253_CR37","doi-asserted-by":"publisher","unstructured":"Neuhauser H, Schienkiewitz A, Rosario AS, Dortschy R, Kurth B-M (2013) Referenzperzentile f\u00fcr anthropometrische Ma\u00dfzahlen und Blutdruck aus der Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS) (report). Robert Koch-Institut. https:\/\/doi.org\/10.25646\/3179","DOI":"10.25646\/3179"},{"key":"3253_CR38","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.4088\/JCP.11m07424","volume":"74","author":"S Pathak","year":"2013","unstructured":"Pathak S, Findling RL, Earley WR, Acevedo LD, Stankowski J, DelBello MP (2013) Efficacy and Safety of Quetiapine in Children and Adolescents With Mania Associated With Bipolar I Disorder: A 3-Week, Double-Blind, Placebo-Controlled Trial. J Clin Psychiatry 74:e100\u2013e109. https:\/\/doi.org\/10.4088\/JCP.11m07424","journal-title":"J Clin Psychiatry"},{"key":"3253_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2014.07.045","volume":"159","author":"R P\u00e9rez-Iglesias","year":"2014","unstructured":"P\u00e9rez-Iglesias R, Ortiz-Garcia de la Foz V, Mart\u00ednez Garc\u00eda O, Amado JA, Garcia-Unzueta MT, Ayesa-Arriola R, Suarez-Pinilla P, Tabares-Seisdedos R, Crespo-Facorro B (2014) Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophr Res 159:90\u201394. https:\/\/doi.org\/10.1016\/j.schres.2014.07.045","journal-title":"Schizophr Res"},{"key":"3253_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29\u201339. https:\/\/doi.org\/10.1016\/s0024-3205(00)00911-5","journal-title":"Life Sci"},{"key":"3253_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2147\/nedt.2007.3.2.219","volume":"3","author":"M Riedel","year":"2007","unstructured":"Riedel M, M\u00fcller N, Strassnig M, Spellmann I, Severus E, M\u00f6ller H-J (2007) Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatr Dis Treat 3:219\u2013235. https:\/\/doi.org\/10.2147\/nedt.2007.3.2.219","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3253_CR42","first-page":"75","volume":"18","author":"M Riedel","year":"2011","unstructured":"Riedel M, Seem\u00fcller F, Schennach R, Musil R, Spellmann I, Oppolzer B, M\u00f6ller H-J, Koehler J, Severus E (2011) Efficacy and tolerability of quetiapine under real-life conditions. Analysis of an observational study in patients with schiophrenia in Germany (CLINIPEP). Psychopharmakotherapie 18:75\u201383","journal-title":"Psychopharmakotherapie"},{"key":"3253_CR43","unstructured":"Sachse J, H\u00e4rtter S, M\u00fcller MJ, Dragicevic A, Hiemke C (2003) Therapeutisches Drug-Monitoring von Quetiapin. PPT Psychopharmakotherapie"},{"key":"3253_CR44","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19cs13169","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Gr\u00fcnder G, the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (2020) Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.19cs13169","journal-title":"J Clin Psychiatry"},{"key":"3253_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/104454601317261591","volume":"11","author":"JA Shaw","year":"2001","unstructured":"Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M (2001) A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415\u2013424. https:\/\/doi.org\/10.1089\/104454601317261591","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"3253_CR46","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.4088\/JCP.09r05739yel","volume":"72","author":"A Sparshatt","year":"2011","unstructured":"Sparshatt A, Taylor D, Patel MX, Kapur S (2011) Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry 72:1108\u20131123. https:\/\/doi.org\/10.4088\/JCP.09r05739yel","journal-title":"J Clin Psychiatry"},{"key":"3253_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.749692","volume":"12","author":"JR Strawn","year":"2021","unstructured":"Strawn JR, Poweleit EA, Uppugunduri CRS, Ramsey LB (2021) Pediatric therapeutic drug monitoring for selective serotonin reuptake inhibitors. Front Pharmacol 12:749692. https:\/\/doi.org\/10.3389\/fphar.2021.749692","journal-title":"Front Pharmacol"},{"key":"3253_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/01.jcp.0000084034.22282.78","volume":"23","author":"R Tandon","year":"2003","unstructured":"Tandon R (2003) Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia. J Clin Psychopharmacol 23:15\u201320. https:\/\/doi.org\/10.1097\/01.jcp.0000084034.22282.78","journal-title":"J Clin Psychopharmacol"},{"key":"3253_CR49","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00702-022-02485-6","volume":"129","author":"R Taurines","year":"2022","unstructured":"Taurines R, Fekete S, Preuss-Wiedenhoff A, Warnke A, Wewetzer C, Plener P, Burger R, Gerlach M, Romanos M, Egberts KM (2022) Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. J Neural Transm 129:689\u2013701. https:\/\/doi.org\/10.1007\/s00702-022-02485-6","journal-title":"J Neural Transm"},{"key":"3253_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","volume":"19","author":"B Vitiello","year":"2009","unstructured":"Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C (2009) Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19:629\u2013635. https:\/\/doi.org\/10.1016\/j.euroneuro.2009.04.008","journal-title":"Eur Neuropsychopharmacol"},{"key":"3253_CR51","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/01.jcp.0000185427.08268.db","volume":"25","author":"U Weiss","year":"2005","unstructured":"Weiss U, Marksteiner J, Kemmler G, Saria A, Aichhorn W (2005) Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 25:570\u2013574. https:\/\/doi.org\/10.1097\/01.jcp.0000185427.08268.db","journal-title":"J Clin Psychopharmacol"},{"key":"3253_CR52","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/cap.2007.0084","volume":"18","author":"HR Winter","year":"2008","unstructured":"Winter HR, Earley WR, Hamer-Maansson JE, Davis PC, Smith MA (2008) Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 18:81\u201398. https:\/\/doi.org\/10.1089\/cap.2007.0084","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"3253_CR53","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/YIC.0b013e3283430a0e","volume":"26","author":"S Zhornitsky","year":"2011","unstructured":"Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompr\u00e9 P-P, Stip E (2011) Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol 26:183\u2013192. https:\/\/doi.org\/10.1097\/YIC.0b013e3283430a0e","journal-title":"Int Clin Psychopharmacol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03253-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:19:07Z","timestamp":1792577947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03253-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03253-6","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KE, MR, RT and PP received grant research support from BfArM.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted adhering to the principles of Good Clinical Practice and the Declaration of Helsinki. The independent ethics committees of all participating centers approved the study (University Hospital of Wuerzburg study number 301\/13_ff).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}